The ASX has been trading flat at around 7,922 points on Friday.
Staples has been the best-performing sector, up 3%, followed by Industrials and Utilities, both up 0.5%.
Health Care has been the worst-performing, down 0.6%, followed by Information Technology, down 0.5%, and Energy, down 0.33%.
Telix Pharmaceuticals (ASX:TLX) has been the most watched on HotCopper forums today following the U.S. FDA’s approval for its New Drug Application (NDA) for Gozellix, the company’s next-generation imaging agent for prostate cancer.
Also trending is CZR Resources (ASX:CZR) after inking a deal with Robe River Joint Venture (Robe) to divest CZR’s interest in several tenements including the Robe Mesa Iron Ore project for cash consideration of A$75 million.
Rounding out the most discussed today has been Paladin Energy (ASX:PDN) after its Langer Heinrich Mine was impacted by “unseasonal” heavy rains in Namibia.
You’re up to date – see you later for HotCopper’s Market Close.
More market news
51st State: What is Trump’s endgame with tariffs – and what will it mean for Canada?
Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst
Join the discussion: See what’s trending right now on Australia’s largest stock forum and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.